These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36732592)

  • 21. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    BMC Cancer; 2019 Jun; 19(1):605. PubMed ID: 31221124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status.
    Løvig T; Meling GI; Diep CB; Thorstensen L; Norheim Andersen S; Lothe RA; Rognum TO
    Scand J Gastroenterol; 2002 Oct; 37(10):1184-93. PubMed ID: 12408524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.
    Liu F; Zhong F; Wu H; Che K; Shi J; Wu N; Fu Y; Wang Y; Hu J; Qian X; Fan X; Wang W; Wei J
    Oncologist; 2023 Mar; 28(3):e136-e144. PubMed ID: 36724040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.
    Wang Z; Wang X; Xu Y; Li J; Zhang X; Peng Z; Hu Y; Zhao X; Dong K; Zhang B; Gao C; Zhao X; Chen H; Cai J; Bai Y; Sun Y; Shen L
    BMC Med; 2022 Apr; 20(1):133. PubMed ID: 35443723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
    Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
    Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.
    Wang D; Chen X; Du Y; Li X; Ying L; Lu Y; Shen B; Gao X; Yi X; Xia X; Sui X; Shu Y
    Front Immunol; 2022; 13():799988. PubMed ID: 35281032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.
    Akagi K; Oki E; Taniguchi H; Nakatani K; Aoki D; Kuwata T; Yoshino T
    Cancer Sci; 2021 Mar; 112(3):1105-1113. PubMed ID: 33403729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer neoantigens as potential targets for immunotherapy.
    Ma W; Pham B; Li T
    Clin Exp Metastasis; 2022 Feb; 39(1):51-60. PubMed ID: 33950415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.
    Scheel SK; Porzner M; Pfeiffer S; Ormanns S; Kirchner T; Jung A
    BMC Cancer; 2010 Aug; 10():413. PubMed ID: 20696052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frameshift mutations of a tumor suppressor gene ZNF292 in gastric and colorectal cancers with high microsatellite instability.
    Lee JH; Song SY; Kim MS; Yoo NJ; Lee SH
    APMIS; 2016 Jul; 124(7):556-60. PubMed ID: 27150435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cells of colorectal cancer patients' stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells.
    Schwarz S; Schmitz J; Löffler MW; Ghosh M; Rammensee HG; Olshvang E; Markel M; Mockel-Tenbrinck N; Dzionek A; Krake S; Arslan B; Kampe KD; Wendt A; Bauer P; Mullins CS; Schlosser A; Linnebacher M
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
    Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
    Bond CE; McKeone DM; Kalimutho M; Bettington ML; Pearson SA; Dumenil TD; Wockner LF; Burge M; Leggett BA; Whitehall VL
    Oncotarget; 2016 Oct; 7(43):70589-70600. PubMed ID: 27661107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC.
    Kanemura H; Hayashi H; Tomida S; Tanizaki J; Suzuki S; Kawanaka Y; Tsuya A; Fukuda Y; Kaneda H; Kudo K; Takahama T; Imai R; Haratani K; Chiba Y; Otani T; Ito A; Sakai K; Nishio K; Nakagawa K
    JTO Clin Res Rep; 2022 Aug; 3(8):100373. PubMed ID: 35941997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
    Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.